帕瑞昔布用于术后疼痛管理超过3天时的安全性。
Safety of parecoxib when used for more than 3 days for the management of postoperative pain.
作者信息
Essex Margaret Noyes, Cheung Raymond, Li Chunming, Xie Li
机构信息
Global Medical Affairs, Pfizer Inc., 235 East 42nd St, New York, NY 10017, USA.
Biostatistics & Analysis, Pfizer Inc., 1 Giralda Farms, Madison, NJ 07940, USA.
出版信息
Pain Manag. 2017 Sep;7(5):383-389. doi: 10.2217/pmt-2017-0017. Epub 2017 Jun 7.
AIM
To assess parecoxib safety when used for >3 days for postoperative pain management.
METHODS
Treatment-emergent adverse event (TEAE) occurrence after day 3 was examined in a pooled analysis of three placebo-controlled trials of parecoxib following general or gynecologic surgery, or total hip arthroplasty. A total of 358 patients received parecoxib, and 318 placebo.
RESULTS
Mean treatment duration was similar between treatment groups. The overall frequency of all TEAEs after day 3 was also similar between treatment groups. Most TEAEs occurred in <1% of patients after day 3; frequencies were similar between treatment groups. Most TEAEs were considered mild or moderate in severity.
CONCLUSION
TEAE occurrence in patients receiving parecoxib for >3 days was low and similar to placebo after treatment day 3.
目的
评估帕瑞昔布用于术后疼痛管理超过3天时的安全性。
方法
在一项对帕瑞昔布用于普通外科手术、妇科手术或全髋关节置换术后的三项安慰剂对照试验的汇总分析中，检查第3天之后出现的治疗中出现的不良事件（TEAE）。共有358例患者接受帕瑞昔布治疗，318例接受安慰剂治疗。
结果
各治疗组的平均治疗持续时间相似。第3天之后所有TEAE的总体发生率在各治疗组之间也相似。大多数TEAE在第3天之后发生在不到1%的患者中；各治疗组的发生率相似。大多数TEAE的严重程度被认为是轻度或中度。
结论
接受帕瑞昔布治疗超过3天的患者中TEAE的发生率较低，且在治疗第3天之后与安慰剂相似。
Zotero 插件